Where to report an adverse event officially, by region — a second dataset

Post #11 describes the usual case. This is about the unusual one.

How to document: date, exact symptom or event, severity, duration, outcome, any medical attention sought. Detailed documentation is far more useful than a vague report.

I have kept the units in throughout, for the obvious reason.

Adding the measurement that post #15 says would settle it.

Where to report: in many countries there is a pharmacovigilance system where adverse events can be reported. FDA MedWatch in the US, Yellow Card in UK, EudraVigilance in EU.

Not the answer, but possibly the question that gets there.

Injection-site reactions that spread over a day or come with systemic symptoms are a different observation from ordinary local reactions.

It is one reading of the data and not the only reasonable one.

The published trial rates come from supervised populations on defined schedules and are not comparable to rates derived from who chooses to post.

Nothing to add, except that this is the answer I would give if asked.

Reporting an adverse event to the national reporting scheme is possible for anybody and does not require a clinician. Those schemes exist to catch what trials could not.

It is the sort of thing that seems obvious in retrospect and was not at the time.

Post #20 is the version of this I will quote in future. One addition.

Where a symptom began after an escalation and settled after a reduction, that sequence is the strongest observation an individual can contribute.

A report is more useful with dates, dose, timing relative to dose, and everything else being taken. Without those it cannot be assessed.

Pancreatitis is a genuine serious adverse event to know: severe epigastric pain, back pain, elevated lipase (≥3× upper limit of normal). If this constellation appears, stopping the drug and seeking urgent evaluation is appropriate.

Not a strong opinion, just a consistent one.

Answering the question post #22 raises rather than the one it answers.

Medullary thyroid carcinoma is the reason these compounds are contraindicated in people with personal or family history of MTC or multiple endocrine neoplasia type 2. Rodent toxicology showed a signal; human evidence of causation is absent but caution is appropriate.

That is the shape of it. The detail is where I would expect to be corrected.

The most useful contribution to this subcategory is a completed account: what happened, what was done, and what the outcome was.

Reporting to regulatory agencies: if you have had a serious event, reporting it to the regulatory agency in your country can help with signal detection across the population.

I would rather post the uncertainty than round it away.

Narrowing post #24, because the general version has more than one answer.

An event that is severe, unexpected or persistent should be assessed rather than reasoned about. The asymmetry between the cost of being checked and the cost of being wrong is the whole basis of that.

If anyone can point at the primary source I would be grateful.

That reframing is the whole thing. The facts I already had.

Attribution is genuinely hard for a single case and the reporting schemes are designed to work with that. You are not expected to prove causation to file.

It took me longer than it should have to see that.

Nothing here is medical advice, and in this subcategory the phrase is doing more work than in any other on the site.

On balance I think that is right, and I would not bet much on it.